Our Targets Strategically Reflect:

Assets developed as Best-in-Class or First-in-Class monoclonal antibodies targeting key cellular and biochemical pathways underlying diseases of interest.

Elemental’s targets play a central role in multiple related diseases with significant unmet medical needs.